A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis (NCT04176198)
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
🩺 Plain-English Summary (8th-Grade Level)
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Who can join: Review the eligibility criteria below.
Location: University of Alabama — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (90 Sites)
Showing the first 25 of 90 sites.
- University of Alabama — Birmingham, Alabama
- The University of Arizona Cancer Center — Tucson, Arizona
- City of Hope — Duarte, California
- University of Southern California — Los Angeles, California
- Hoag Family Cancer Institute — Newport Beach, California
- Blood Cancer Center — Denver, Colorado
- Yale School of Medicine — New Haven, Connecticut
- University of Florida Health Shands Cancer Hospital — Gainesville, Florida
- University of Miami — Miami, Florida
- Baptist Health - Miami Cancer Institute — Miami, Florida
- Emory University — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- University of Maryland — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Washington University of Medicine — St Louis, Missouri
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medical Center — New York, New York
- Montefiore Cancer Center — The Bronx, New York
- Duke Cancer Institute — Durham, North Carolina
- Ohio State University — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (617) 674-6800
Email: reyna.bishop@us.sumitomo-pharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelofibrosis
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Birmingham, Alabama
- Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Birmingham, Alabama
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis — Pasadena, California
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) — Newport Beach, California
Explore by condition: All Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.